• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Biochem J . Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp5 main protease

tetano

Editor, Senior Moderator
Biochem J


. 2021 Jul 16;478(13):2499-2515.
doi: 10.1042/BCJ20210197.
Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp5 main protease


Jennifer C Milligan[SUP] #[/SUP][SUP] 1 [/SUP], Theresa U Zeisner[SUP] #[/SUP][SUP] 2 [/SUP], George Papageorgiou[SUP] 3 [/SUP], Dhira Joshi[SUP] 3 [/SUP], Christelle Soudy[SUP] 3 [/SUP], Rachel Ulferts[SUP] 4 [/SUP], Mary Wu[SUP] 5 [/SUP], Chew Theng Lim[SUP] 1 [/SUP], Kang Wei Tan[SUP] 1 [/SUP], Florian Weissmann[SUP] 1 [/SUP], Berta Canal[SUP] 1 [/SUP], Ryo Fujisawa[SUP] 6 [/SUP], Tom Deegan[SUP] 6 [/SUP], Hema Nagaraj[SUP] 3 [/SUP], Ganka Bineva-Todd[SUP] 3 [/SUP], Clovis Basier[SUP] 2 [/SUP], Joseph F Curran[SUP] 2 [/SUP], Michael Howell[SUP] 5 [/SUP], Rupert Beale[SUP] 4 [/SUP], Karim Labib[SUP] 6 [/SUP], Nicola O'Reilly[SUP] 3 [/SUP], John F X Diffley[SUP] 1 [/SUP]



Affiliations

Abstract

The coronavirus 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), spread around the world with unprecedented health and socio-economic effects for the global population. While different vaccines are now being made available, very few antiviral drugs have been approved. The main viral protease (nsp5) of SARS-CoV-2 provides an excellent target for antivirals, due to its essential and conserved function in the viral replication cycle. We have expressed, purified and developed assays for nsp5 protease activity. We screened the nsp5 protease against a custom chemical library of over 5000 characterised pharmaceuticals. We identified calpain inhibitor I and three different peptidyl fluoromethylketones (FMK) as inhibitors of nsp5 activity in vitro, with IC50 values in the low micromolar range. By altering the sequence of our peptidomimetic FMK inhibitors to better mimic the substrate sequence of nsp5, we generated an inhibitor with a subnanomolar IC50. Calpain inhibitor I inhibited viral infection in monkey-derived Vero E6 cells, with an EC50 in the low micromolar range. The most potent and commercially available peptidyl-FMK compound inhibited viral growth in Vero E6 cells to some extent, while our custom peptidyl FMK inhibitor offered a marked antiviral improvement.

Keywords: COVID-19; coronavirus; nsp5; protease.
 
Back
Top Bottom